Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer

A phase 1 study

Silvia Brugnatelli, Marco Danova, Manuela Tamburo De Bella, Marina Vaglica, Giovanna Manuguerra, Alberto Riccardi, Sergio Palmeri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). Methods: Heavily pretreated patients with MBC, aged 18-75 years with World Health Organization performance status of 0-2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m2) followed by a weekly fixed dose of gemcitabine, 800 mg/m2, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if ≥3 of 5 patients at any dose level experienced DLT. Results: Eighteen patients (median age 56 years) received a mean of 4.1 (range 1-6) cycles. Asthenia, stomatitis and leukopenia were the main DLTs. One of 5 patients had DLT at dose level 1 and 2 of 5 patients at dose level 2. At dose level 3, 3 of 5 patients had DLTs. Three additional patients treated at dose level 3 confirmed that the MTD had been reached. Therefore, the recommended docetaxel dose in combination with gemcitabine 800 mg/m2 for phase II studies was established at the next lower dose, 35 mg/m2. Of 12 evaluable patients, 7 (58%) achieved an objective response. Conclusions: Gemcitabine 800 mg/m2 plus docetaxel 35 mg/m2 on days 1, 8 and 15 of a 28-day cycle is a safe regimen which shows activity in heavily pretreated patients with MBC. Further phase II investigations with this combination are now warranted.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalOncology
Volume62
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

docetaxel
gemcitabine
Breast Neoplasms
Asthenia
Stomatitis
Alopecia
Leukopenia

Keywords

  • Docetaxel
  • Dose finding
  • Gemcitabine
  • Metastatic breast cancer
  • Weekly schedule

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer : A phase 1 study. / Brugnatelli, Silvia; Danova, Marco; De Bella, Manuela Tamburo; Vaglica, Marina; Manuguerra, Giovanna; Riccardi, Alberto; Palmeri, Sergio.

In: Oncology, Vol. 62, No. 1, 2002, p. 33-38.

Research output: Contribution to journalArticle

Brugnatelli, Silvia ; Danova, Marco ; De Bella, Manuela Tamburo ; Vaglica, Marina ; Manuguerra, Giovanna ; Riccardi, Alberto ; Palmeri, Sergio. / Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer : A phase 1 study. In: Oncology. 2002 ; Vol. 62, No. 1. pp. 33-38.
@article{31b45a36e44c4801a299a7cbb2312381,
title = "Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: A phase 1 study",
abstract = "Objective: This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). Methods: Heavily pretreated patients with MBC, aged 18-75 years with World Health Organization performance status of 0-2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m2) followed by a weekly fixed dose of gemcitabine, 800 mg/m2, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if ≥3 of 5 patients at any dose level experienced DLT. Results: Eighteen patients (median age 56 years) received a mean of 4.1 (range 1-6) cycles. Asthenia, stomatitis and leukopenia were the main DLTs. One of 5 patients had DLT at dose level 1 and 2 of 5 patients at dose level 2. At dose level 3, 3 of 5 patients had DLTs. Three additional patients treated at dose level 3 confirmed that the MTD had been reached. Therefore, the recommended docetaxel dose in combination with gemcitabine 800 mg/m2 for phase II studies was established at the next lower dose, 35 mg/m2. Of 12 evaluable patients, 7 (58{\%}) achieved an objective response. Conclusions: Gemcitabine 800 mg/m2 plus docetaxel 35 mg/m2 on days 1, 8 and 15 of a 28-day cycle is a safe regimen which shows activity in heavily pretreated patients with MBC. Further phase II investigations with this combination are now warranted.",
keywords = "Docetaxel, Dose finding, Gemcitabine, Metastatic breast cancer, Weekly schedule",
author = "Silvia Brugnatelli and Marco Danova and {De Bella}, {Manuela Tamburo} and Marina Vaglica and Giovanna Manuguerra and Alberto Riccardi and Sergio Palmeri",
year = "2002",
doi = "10.1159/000048244",
language = "English",
volume = "62",
pages = "33--38",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer

T2 - A phase 1 study

AU - Brugnatelli, Silvia

AU - Danova, Marco

AU - De Bella, Manuela Tamburo

AU - Vaglica, Marina

AU - Manuguerra, Giovanna

AU - Riccardi, Alberto

AU - Palmeri, Sergio

PY - 2002

Y1 - 2002

N2 - Objective: This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). Methods: Heavily pretreated patients with MBC, aged 18-75 years with World Health Organization performance status of 0-2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m2) followed by a weekly fixed dose of gemcitabine, 800 mg/m2, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if ≥3 of 5 patients at any dose level experienced DLT. Results: Eighteen patients (median age 56 years) received a mean of 4.1 (range 1-6) cycles. Asthenia, stomatitis and leukopenia were the main DLTs. One of 5 patients had DLT at dose level 1 and 2 of 5 patients at dose level 2. At dose level 3, 3 of 5 patients had DLTs. Three additional patients treated at dose level 3 confirmed that the MTD had been reached. Therefore, the recommended docetaxel dose in combination with gemcitabine 800 mg/m2 for phase II studies was established at the next lower dose, 35 mg/m2. Of 12 evaluable patients, 7 (58%) achieved an objective response. Conclusions: Gemcitabine 800 mg/m2 plus docetaxel 35 mg/m2 on days 1, 8 and 15 of a 28-day cycle is a safe regimen which shows activity in heavily pretreated patients with MBC. Further phase II investigations with this combination are now warranted.

AB - Objective: This study was designed to determine the maximum tolerable dose (MTD) of gemcitabine plus docetaxel, both given on a weekly schedule, in patients with pretreated metastatic breast cancer (MBC). Methods: Heavily pretreated patients with MBC, aged 18-75 years with World Health Organization performance status of 0-2 were enrolled. Three escalating weekly doses of docetaxel (30, 35 and 40 mg/m2) followed by a weekly fixed dose of gemcitabine, 800 mg/m2, were administered on days 1, 8 and 15 of a 28-day cycle. Dose-limiting toxicity (DLT) included grade >3 hematologic toxicity and grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if ≥3 of 5 patients at any dose level experienced DLT. Results: Eighteen patients (median age 56 years) received a mean of 4.1 (range 1-6) cycles. Asthenia, stomatitis and leukopenia were the main DLTs. One of 5 patients had DLT at dose level 1 and 2 of 5 patients at dose level 2. At dose level 3, 3 of 5 patients had DLTs. Three additional patients treated at dose level 3 confirmed that the MTD had been reached. Therefore, the recommended docetaxel dose in combination with gemcitabine 800 mg/m2 for phase II studies was established at the next lower dose, 35 mg/m2. Of 12 evaluable patients, 7 (58%) achieved an objective response. Conclusions: Gemcitabine 800 mg/m2 plus docetaxel 35 mg/m2 on days 1, 8 and 15 of a 28-day cycle is a safe regimen which shows activity in heavily pretreated patients with MBC. Further phase II investigations with this combination are now warranted.

KW - Docetaxel

KW - Dose finding

KW - Gemcitabine

KW - Metastatic breast cancer

KW - Weekly schedule

UR - http://www.scopus.com/inward/record.url?scp=0036159860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036159860&partnerID=8YFLogxK

U2 - 10.1159/000048244

DO - 10.1159/000048244

M3 - Article

VL - 62

SP - 33

EP - 38

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -